title: Cytoreductive radical prostatectomy in metastatic prostate cancer: Does it really make sense?
abstract: OBJECTIVE
  Surgical removal of the primary tumor in metastatic prostate cancer (mPCa) is becoming a hotly debated issue. The purpose of this review was to summarize the current knowledge on cytoreductive radical prostatectomy (cRP) in this setting.
  
  
  METHODS
  We performed a non-systematic Medline/PubMed literature search of articles published in the field between January 2000 and April 2015.
  
  
  RESULTS
  Cytoreductive surgery has demonstrated its benefit in various malignancies with a solid biological rationale to justify its assessment in mPCa. cRP appears as a safe and feasible procedure in expert hands and well-selected patients. A growing body of evidence suggests a survival benefit for patients undergoing cRP as a part of a multimodal approach compared to those treated with systemic treatment alone. Nevertheless, little is known about the best clinical and tumor characteristics for the selection of patients most likely to benefit from cRP. The current literature is based on retrospective studies with small cohorts and limited follow-up or large uncontrolled population-based studies.
  
  
  CONCLUSIONS
  Data from various other malignancies together with the biological rationale and preliminary results in PCa suggest that cytoreductive surgery may be an option in some mPCa patients. The lack of randomized controlled trials and the low level of evidence in the current literature preclude any firms conclusion on the benefit of cRP in mPCa. Ongoing phase II and future phase III studies are mandatory to define the exact role of cRP in mPCa and to identify the patients who are most likely to benefit from cRP.
authors: Department of Urology, General Hospital, Medical University Vienna, Vienna, Austria.|Department of Urology, Rennes University Hospital, Rennes, France.
authors: Romain
authors: R
authors: Mathieu
authors: Department of Urology, General Hospital, Medical University Vienna, Vienna, Austria.
authors: Stephan M
authors: SM
authors: Korn
authors: Department of Urology, Rennes University Hospital, Rennes, France.
authors: Karim
authors: K
authors: Bensalah
authors: Department of Urology, General Hospital, Medical University Vienna, Vienna, Austria.
authors: Gero
authors: G
authors: Kramer
authors: Department of Urology, General Hospital, Medical University Vienna, Vienna, Austria. shahrokh.shariat@meduniwien.ac.at.|Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA. shahrokh.shariat@meduniwien.ac.at.|Department of Urology, Weill Cornell Medical College, New York, NY, USA. shahrokh.shariat@meduniwien.ac.at.
authors: Shahrokh F
authors: SF
authors: Shariat
mesh_terms: D001859:Bone Neoplasms / Q000556:secondary / Q000628:therapy*; D002277:Carcinoma / Q000556:secondary / Q000628:therapy*; D065426:Cytoreduction Surgical Procedures / Q000379:methods*; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology; D008207:Lymphatic Metastasis; D008297:Male; D009362:Neoplasm Metastasis; D011468:Prostatectomy / Q000379:methods*; D011471:Prostatic Neoplasms / Q000473:pathology / Q000601:surgery*; D015996:Survival Rate
keywords: Cytoreductive surgical procedures; Metastatic prostate cancer; Outcome; Radical prostatectomy